Galmed Pharma rises after positive results of liver drug formulation study
Brief: Galmed Announces Meaningful Top Line Results From Am-001 Study Of Aramchol Meglumine
Brief: Galmed Announces Top-Line Results In Oncology MoA Studies A 3-Drug Combination Of Aramchol, Stivarga® And Metformin Significantly Enhanced Gi Tumor Cells, Killing In-Vivo And In-Vitro
Galmed Pharmaceuticals Ltd reports results for the quarter ended June 30 - Earnings Summary
Brief: Galmed Pharmaceuticals Ltd Approves Increase In Authorized Share Capital To 900M Shares
Galmed Pharmaceuticals Ltd expected to post a loss of 83 cents a share - Earnings Preview
Brief: Galmed Pharmaceuticals Files Prospectus Related To Offer & Sale Of Up To 7.5 Million Ordinary Shares By Selling Stockholder
Brief: Galmed Announces First Time Results In Oncology Studies Aramchol Significantly Enhances Bayer's Regorafenib Effect In Gi Cancer Models
Galmed Pharma soars on under-the-tongue semaglutide development deal
Brief: Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation
Brief: Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers
Galmed Pharmaceuticals falls after Maxim downgrade
U.S. STOCKS ON THE MOVE-Children's Place, US energy sector, retailers
Galmed surges on plans to expand into cancer and heart disease drug development
Brief: Galmed To Expand Drug Development Activities To Cancer, Cardiometabolic Diseases
Brief: Galmed Pharmaceuticals Says Nasdaq Notified Co That It Had Regained Compliance With Minimum Bid Price Requirement
Galmed Pharmaceuticals Ltd expected to post a share - Earnings Preview
Galmed Pharmaceuticals Ltd expected to post a loss of 32 cents a share - Earnings Preview
Brief: Galmed Pharmaceuticals Got Letter From Nasdaq Granted Additional 180 Calendar Day Period To Regain Compliance